Stock Evaluator: Ocular Therapeutix, Inc. (OCUL)

Ocular Therapeutix, Inc. OCUL

$6.02 0.01 0.17%
November 17, 2026 4:00:00 PM EST November 10, 2021 Volume: 6,296,598
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics OCUL Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $1,322.3 $436.9 50%
Shares Out (Mil) 225.5 46.5 78%
Institutional Ownership 98.5% 82.2% 79%
Float (Mil) 185.1 47.7 72%
Beta 1.22 0.68 71%
Avg Daily Volume (000s) 3,220 339 86%
Price Change
(52-week)
(46.8%) 52.1% 22%
Growth OCUL Industry
Median
Percentile
(All Stocks)
Sales (5yr) 24.5% 6.6% 86%
Net Income (5yr) (11.3%) (1.6%) 28%
EPS (5yr) 11.1% 15.1% 49
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (8.4%) (15.1%) 59%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 6 5 6
Current EPS ($0.416) ($1.530) ($1.594)
Month Ago EPS ($0.378) ($1.444) ($1.480)
# Rev Up 0 0 0
# Rev Down 1 0 0
Three Months Ago EPS ($0.376) ($1.430) ($1.454)
Year/Year Chg (1.0%) 7.7% (15.9%)
Financials OCUL Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $50 $289 20%
Net Income (TTM) (Mil) ($327) ($11) 4%
EPS (TTM) ($1.457) ($0.600) 17%
Operating Cash Flow (TTM) (Mil) ($253) ($7) 3%
Net Cash Flow (TTM) (Mil) $186 $1 83%
Long-Term Debt (Q1) (Mil) $77 $6 42%
Enterprise Value (Q1) (Mil) $1,057 $331 42%
Valuation OCUL Industry
Median
Percentile
(All Stocks)
P/B 2.99 2.15 69%
P/E na 24.2 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.2 na
Ratios OCUL Industry
Median
Percentile
(All Stocks)
Gross Margin (400.8%) 69.5% 0%
Net Margin (648.6%) 3.6% 1%
ROA (64.3%) (23.3%) 9%
ROE (93.5%) (24.7%) 10%
Liabilities to Assets 27.2% 31.8% 19%
F-Score 2 3 7%

Ocular Therapeutix, Inc. did not pass any screens on 11/17/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors